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In adults with end-stage liver disease concurrent changes in pro- and antihemostatic 
pathways result in a rebalanced hemostasis. Children though, have a developing hemo-
static system, different disease etiologies, and increased risk of thrombosis. This study 
aimed to assess the hemostatic state of children during and after liver transplantation. 
Serial blood samples were obtained from 20 children (≤16 years) undergoing primary 
liver transplantation (September 2017-October 2018). Routine hemostasis tests, throm-
bomodulin-modified thrombin generation, clot lysis times, and hemostatic proteins were 
measured. Reference values were established using an age-matched control group of 30 
children. Thrombocytopenia was present in study patients. Von Willebrand factors were 
doubled and ADAMTS13 levels decreased during and after transplantation up until day 
30, when platelet count had normalized. Whereas prothrombin time and activated partial 
thromboplastin time were prolonged during transplantation, thrombin generation was 
within normal ranges, except during perioperative heparin administration. Fibrinogen, 
factor VIII levels, and clot lysis time were elevated up until day 30. In conclusion, children 
with end-stage liver disease are in tight hemostatic balance. During transplantation a tem-
porary heparin-dependent hypocoagulable state is present, which rapidly converts to a 
hemostatic balance with distinct hypercoagulable features that persist until at least day 
30. This hypercoagulable state may contribute to the risk of posttransplant thrombosis.
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1  | INTRODUC TION
Bleeding and thrombosis are serious causes of morbidity and mor-
tality in pediatric liver transplantation.1-4 Incidences of 5%-18% for 
hepatic artery thrombosis and 5%-10% for portal vein thrombosis 
have been reported.1-3,5 Bleeding complications occur in 5%-20% 
and may complicate surgery, warranting proactive hemostatic man-
agement.4,6 It remains unpredictable which patients are at risk of 
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thrombotic complications and which patients are at risk of bleeding 
complications.
In contrast to the historical view that patients with end-stage liver 
disease have an increased bleeding tendency, over the past decade 
it has been demonstrated that adult patients are in a state of “rebal-
anced hemostasis.”7,8 Conventional coagulation tests such as pro-
thrombin time (PT) and activated partial thromboplastin time (APTT) 
suggest a hypocoagulable state in these patients, but these tests only 
indicate decrease in procoagulant proteins and are unable to measure 
the concurrent reduction of anticoagulant proteins.9 More advanced 
hemostatic tests such as thrombomodulin-modified thrombin gener-
ation assays have demonstrated intact or enhanced thrombin genera-
tion, indicating a normal to hypercoagulable hemostatic state in these 
patients.10-13
This rebalanced hemostatic state is the result of a commen-
surate decrease in pro- and antihemostatic factors occurring in 
adults with end-stage liver disease, affecting primary hemostasis, 
coagulation, and fibrinolysis (Table S1). Regarding primary hemo-
stasis, thrombocytopenia is present in most patients. Meanwhile, 
increased levels of platelet adhesive protein von Willebrand factor 
(VWF), combined with decreased levels of VWF-cleaving protease, 
a disintegrin and metalloproteinase with thrombospondin motifs 
type 13 (ADAMTS13), provide adequate platelet adhesion and ag-
gregation.14,15 Similarly, although plasma levels of fibrinogen and 
procoagulant proteins are decreased, these defects are balanced by 
a simultaneous decline in plasma levels of the natural anticoagu-
lants and with this adequate thrombin generation is still achieved.7,8 
Fibrinolysis is also reequilibrated, as low plasminogen levels are 
compensated by decreased levels of fibrinolytic inhibitors, and in-
creased plasminogen activator levels by increased plasminogen ac-
tivator inhibitor type 1 (PAI-1).16,17 Notably though, little is needed 
to disturb this delicate balance, which may degenerate into a hypo- 
or hypercoagulable state, especially during invasive procedures 
such as liver transplantation when pro- and antihemostatic factors 
decrease even further.18-21
Pediatric patients have different disease etiologies, higher inci-
dences of posttransplant thrombosis and a still developing hemostatic 
system.22,23 Hemostasis is an evolving age-dependent process that be-
gins in utero and continues throughout life. Because most maturation 
of the hemostatic system occurs in childhood, hemostasis in children is 
characterized by age-related changes in the coagulation system, with 
most hemostatic proteins present in lower levels in children compared 
to adults.
Up to now, there is a lack of data on the hemostatic state in pediat-
ric patients with liver disease. Thrombin generation capacity in pediatric 
patients with liver diseases has previously been studied by Magnusson 
et al,24 who reported comparable thrombin generation capacity in pa-
tients and age-matched healthy controls. Notably, PT and APTT levels 
were comparable for their study patients and controls, suggesting these 
patients were in a relatively early disease stage. More knowledge of the 
hemostatic state in pediatric patients is required to safely and efficiently 
prevent and treat both thrombotic and bleeding complications during 
liver transplantation.
The aim of this study was to assess hemostatic balance in pedi-
atric patients undergoing liver transplantation. We hypothesized 
that whereas routine laboratory tests demonstrate a hypocoagula-
ble state, more advanced hemostatic tests would indicate intact or 




This is a prospective exploratory cohort study comparing 20 pediat-
ric patients who underwent a liver transplantation with age-matched 
controls in the University Medical Center Groningen between 
September 2017 and October 2018. The study protocol was a pri-
ori approved by the Medical Ethical Committee (NL61164.042.17). 
Informed consent was obtained from all patients (if ≥12 years) and/
or parents/guardians prior to inclusion.
2.2 | Study participants
All pediatric patients (≤16 years) listed for primary liver transplantation 
were screened for eligibility for this study. Exclusion criteria were acute 
liver failure, retransplantation, or combined organ transplantation. 
Additionally, an age-matched control group was included, consisting of 
30 healthy individuals who underwent minor surgery, specifically ingui-
nal surgery (n = 20), and resection of thyroglossal duct cysts (n = 3) or 
benign soft tissue tumors (n = 7) in our center. Exclusion criteria were 
preterm birth, comorbidities known to affect the hemostatic system, a 
medical history of bleeding or thrombosis, and use of medication affect-
ing hemostasis (Figure 1).
2.3 | Setting
Study patients were treated according to standard clinical practice. Liver 
grafts were classically (n = 1) or piggyback (n = 19) implanted. Vascular 
reconstructions were performed using end-to-end anastomoses, bil-
iary reconstructions with a Roux-and-Y hepaticojejunostomy (n = 19) 
or duct-to-duct anastomosis (n = 1). Immunosuppressive therapy con-
sisted of triple therapy including tacrolimus (Prograft®), with basiliximab 
(Simulect®) and prednisone as induction. To prevent thrombotic com-
plications, all recipients received continuous intravenous unfraction-
ated heparin posttransplantation for 1 week, followed by 3 months oral 
acetylsalicylic acid, according to our antithrombotic therapy protocol 
(Figure 2). Continuous infusion of unfractionated heparin was started 
at the end of transplantation or shortly afterwards, if PT values were 
<20 seconds, APTT < 50 seconds, and platelet counts >30 × 109/L. 
In some cases, heparin infusion was already started after graft reper-
fusion, based on the clinical judgment of the transplant surgeon and 
anesthesiologist.
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2.4 | Data collection
Patient and donor characteristics were documented, including trans-
plant-specific details and perioperative administered blood and coagu-
lation products. To assess hemostasis, blood samples were obtained 
from study patients at the following time points: 30 minutes after 
induction of anesthesia, 30 minutes after start of anhepatic phase, 
30 minutes after reperfusion, the end of transplantation, days 1, 3, 
6, and 30 after transplantation. Blood samples in the control group 
were drawn after induction of anesthesia for minor surgery. Samples 
were drawn by venipuncture or derived from central venous lines in 
3.2% sodium citrate tubes. After collection samples were double cen-
trifuged at 18°C for 10 minutes at 2000 and 10 000 g, respectively, 
and subsequently stored at −80°C until use.
2.5 | Hemostatic assays
Primary hemostasis was assessed by measuring platelet count (in our rou-
tine diagnostic laboratory), levels of VWF, and ADAMTS13. VWF levels 
were determined with an enzyme-linked immunosorbent assay (ELISA) 
using commercially available polyclonal antibodies against VWF (DAKO, 
Santa Clara, CA). Plasma activity of ADAMTS13 was measured using the 
FRETS-VWF73 assay (Peptanova, Sandhausen, Germany) as previously 
described by Kokame et al,27,28 with the addition of bilirubin oxidase.
Coagulation was examined with routine tests including PT and 
APTT and by measuring plasma levels of more specific markers includ-
ing fibrinogen, factor II, VIII, and antithrombin by using an automated 
coagulation analyzer (ACL 300 TOP) with reagents (Recombiplastin 2G 
for PT and factor II; Hemosil SynthaSil for APTT, fibrinogen and factor 
VIII; Liquid Antithrombin reagent for antithrombin), and protocols from 
the manufacturer (Instrumentation Laboratory, Bedford, MA). Factor 
levels are given as percentages relative to pooled normal plasma. 
Thrombin generation assays were performed in platelet-poor plasma 
samples by using the fluorimetric method as previously described by 
Hemker et al.29 Thrombin generation capacity was measured with 
calibrated automated thrombography, in clotting plasma in the pres-
ence of thrombomodulin using a micro titer plate reading fluorometer 
(Fluoroskan Ascent) with reagents and protocols from Thrombinoscope 
(Maastricht, the Netherlands). Results were showed as the area under 
the thrombin generation curve, or so called endogenous thrombin po-
tential (ETP; nM IIa*min).
Fibrinolysis was assessed by clot lysis time (CLT) and PAI-1 levels. 
CLT was determined by monitoring changes in turbidity during clot 
formation and subsequent lysis by exogenous tissue plasminogen 
activator as described previously.30 PAI-1 levels were determined 
with an ELISA kit (R&D Systems, Minneapolis, MN).
2.6 | Statistical analysis
Data are presented as mean (standard deviation), median (interquar-
tile range; IQR), or number (percentage) as appropriate. To test for dif-
ferences between study and control group, Mann-Whitney U test and 
Pearson chi-square tests were used for continuous and categorical 
variables, respectively. Potential differences in the thrombin genera-
tion parameters at different time points in study group were com-
pared to the values in the reference group with the Kruskal Wallis 
analysis using the Dunn's-post tests. All reported P values are 2-tailed 
and considered statistically significant if <.05. Statistical analyses 
were performed using IBM Statistics SPSS, version 23 (IBM Inc) and 
GraphPad Prism 7.02.
F I G U R E  1   Flowchart of patients included in the study group and control group
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3  | RESULTS
3.1 | Baseline characteristics
Twenty pediatric liver transplant recipients were included in this 
study with a median age of 2.3 (IQR 0.6-6.0) years, 55% was female 
(Table 1). Indications for liver transplantation were biliary atresia 
(45%), congenital cholestasis (30%), metabolic diseases (20%), and 
hepatoblastoma (5%). Sixteen partial and four full-size grafts were 
derived from 13 living and 7 postmortal donors (Table 2). Baseline 
characteristics were comparable for study and control group.
3.2 | Primary hemostasis
Before, during, and after transplantation thrombocytopenia was pre-
sent in most study patients, which normalized 30 days after trans-
plantation (Figure 3A). Conversely, elevated VWF levels were present 
in study patients from start to end of transplantation and further in-
creased in the week after transplantation. An opposite trend was seen 
for ADAMTS13, which was reduced in study patients at start of trans-
plantation and further decreased during and after transplantation. A 
substantial number of patients had undetectable ADAMTS13 levels 
TA B L E  1   Basic characteristics of study group (pediatric patients 
undergoing liver transplantation) and control group (pediatric 





(n = 30) P value
Gender, female 11 (55%) 11 (37%) .20
Age, y 2.3 (0.6-6.0) 3.3 (1.2-5.7) .62
Weight, kg 14 (8-21) 16 (11-22) .31
Length, cm 90 (68-114) 108 (83-124) .09
Note: Data presented as median (interquartile range) or number (%) 
where appropriate. P value using two sample Mann-Whitney U test and 
Pearson chi-square tests.
F I G U R E  2   Clinical practice protocol regarding hemostasis and antithrombotic therapy in pediatric liver transplantation. FFP, fresh frozen 
plasma; PT, prothrombin time; APTT, activated partial thromboplastin time; ATIII, antithrombin III
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at certain time points. Both VWF and ADAMTS13 were outside our 
reference ranges at 30 days after transplantation (Figure 3B, C).
3.3 | Coagulation
Routine laboratory tests PT and APTT were substantially prolonged 
in study patients at start of transplantation (Figure 4A, B) and further 
prolonged during transplantation. In half of study patients no clot for-
mation was measured after reperfusion and/or at the end of trans-
plantation. Posttransplantation PT and APTT gradually shortened and 
normalized on day 6. From days 1 to 6, APTT levels were influenced by 
continuous administration of intravenous heparin, the dose of which 
was guided by APTT levels, targeting 50-65 seconds (Figure 4B).
In contrast to the PT and APTT, the ETP was comparable for study 
patients and controls at baseline. After reperfusion ETP dropped sig-
nificantly below the level of controls, which could be the result of lo-
cally supplied heparin during generation of the vascular anastomosis. 
Indeed heparin was detected in peripheral blood samples taken after 
reperfusion (Figure 4C, D). The ETP normalized at the end of transplan-
tation and was decreased from days 1 to 6 posttransplantation under 
continuous heparin administration. ETPs levels were significantly 
lower in patients with detectable heparin concentrations than in pa-
tients without detectable heparin concentrations (44 vs 535 nmol/L IIa 
*min; P < .001). Thirty days after transplantation, both PT and APTT as 
well as ETPs were comparable in study patients and controls.
Preoperatively, prothrombin and antithrombin levels were de-
creased in study patients, further decreased during surgery, and 
normalized on day 30. Fibrinogen levels were also low at the start 
of surgery but recovered to supranormal levels on day 30. Factor 
VIII levels were high at the start of surgery, low during surgery, and 
recovered to supranormal levels at day 30 (Figure 5).
3.4 | Fibrinolysis
CLT was comparable for study and control group at start of transplan-
tation, although the variation in CLT was much more profound in study 
patients. CLT was low after reperfusion, and at end of transplantation 
CLT was significantly prolonged in study patients, with no detectable 
fibrinolysis in the majority of patients. In the early postoperative pe-
riod, CLT was variable but comparable to controls, but was prolonged 
at 30 days after transplantation. PAI-1 was significantly higher than 
controls during the perioperative period in study patients (Figure 6).
4  | DISCUSSION
This study shows that pediatric patients with end-stage liver disease 
are in a normal to hypercoagulable hemostatic state. During and 
shortly after liver transplantation, a temporary heparin-dependent 
hypocoagulable state develops, which reverses to hemostatic balance 
with distinct hypercoagulable features on day 30. These observations 
TA B L E  2   Basic characteristics of pediatric patients undergoing 
liver transplantation
 (n = 20)
Pretransplant characteristics
Indication for transplantation
Biliary atresia 9 (45%)
Congenital cholestasis 6 (30%)
Metabolic 4 (20%)
Hepatoblastoma 1 (5%)
PELD score 28 (28-30)
Lab MELD score 15 (6-22)
High urgency 3 (15%)
Previous portal vein thrombosis 2 (10%)
Hemoglobin, mmol/L 5.8 (4.7-6.4)
Platelet count, 109/L 145 (98-195)
Serum creatinine, µmol/L 21 (15-37)
Serum bilirubin, µmol/L 213 (36-355)
Aspartate aminotransferase, U/L 114 (75-215)
Alanine transaminase, U/L 76 (48-106)
International normalized ratio 1.4 (1.1-1.8)
Donor characteristics
Gender, female 8 (40%)
Age, y 33 (23-43)
Weight, kg 76 (65-83)
Length, cm 174 (165-182)
Donor type
Living donor 13 (65%)
Brain death 5 (25%)
Circulatory death 2 (10%)
Graft type
Left lateral segments 15 (75%)
Left lobe 1 (5%)
Full size 4 (20%)
Graft weight, g 316 (254-413)
Graft/recipient weight ratio 2.3 (1.7-3.4)
Surgical characteristics
Cold ischemia time, min 61 (47-404)
Warm ischemia time, min 34 (29-39)
Operation time, min 472 (426-526)
Blood loss, mL/kg 67 (35-116)
Blood transfusion, mL/kg 32 (13-68)
Platelet transfusion, mL/kg 0 (0-18)a
FFP transfusion, mL/kg 0 (0-52)a
Fibrinogen, mg/kg 0 (0-15)a
Note: Data presented as median (interquartile range) or number (%) 
where appropriate. P value using two sample Mann-Whitney U test and 
Pearson chi-square tests.
Abbreviations: FFP, fresh frozen plasma; MELD score, model for end-
stage liver disease score; PELD score, pediatric end-stage liver disease 
score; U/L, units per liter.
aRanges instead of interquartile range values are given. 
6  |     WERNER Et al.
extend our previous findings on hemostatic balance in adults with end-
stage liver disease.13,25 The results of this study suggest that restrictive 
transfusion policy and proactive postoperative antithrombotic treat-
ment, as is increasingly used in the adult population, is justified.7,31
Notably, whereas conventional laboratory tests (platelet count, 
PT, APTT) are suggestive of a hypocoagulable state prior to, during, 
and shortly after pediatric liver transplantation, analyses using 
state-of-the-art hemostasis tests are indicative of rebalanced 
hemostasis. Specifically, we found a profound VWF/ADAMTS13 
unbalance that likely counteracts thrombocytopenia, intact sec-
ondary hemostasis, and normal to defective fibrinolytic capacity.
If we compare our results in pediatric patients to those of adult 
patients with end-stage liver disease, both PT and APTT showed 
comparable changes over time during liver transplantation, with 
maximal values during reperfusion and at end of transplantation re-
spectively. For ETP values, at the start of transplantation ETP values 
in adults are significantly elevated compared to controls, whereas 
in pediatric patients levels were comparable with those in age-
matched controls.25 During transplantation a comparable evolution 
of parameters over time was present in pediatrics compared to con-
trols with one notable exception. In the first week posttransplanta-
tion, ETPs in pediatric patients were very low, whereas in adults ETP 
values were higher in patients compared to controls. This is likely 
the result of the intravenous administration of unfractionated hepa-
rin to pediatric patients, which is not performed in adults.
In aggregate, our data suggest that prior to transplantation, pe-
diatric patients with end-stage liver disease do not have a tendency 
to hemostasis-related bleeding, although they may have a bleeding 
tendency related to portal hypertension. Intraoperatively, the use 
of local supplied heparin results in systemic heparinization, and 
combined with the temporary hyperfibrinolytic state after reper-
fusion, may contribute to perioperative bleeding.32 In the early 
F I G U R E  3   Platelet count (A), VWF (B), and ADAMTS13 (C) levels at various time points in 20 pediatric patients during and after liver 
transplantation and in 30 healthy controls. Small horizontal lines indicate medians. Blue horizontal dotted lines indicate reference values 
(A). Anhep, anhepatic phase; Reperf, reperfusion phase; VWF, von Willebrand factor; ADAMTS13, a disintegrin and metalloproteinase with 


































































































**     **     **     **     **     **     **     **
F I G U R E  4   PT (A), APTT (B), thrombin 
generation capacity (C), and heparin 
concentrations (D) at various time points 
in 20 pediatric patients during and after 
liver transplantation and in 30 healthy 
controls. The small horizontal lines 
indicate medians. The horizontal blue 
highlighted area at 50 and 65 s. indicate 
target levels for heparin dosage (B). 
Thrombin generation capacity estimated 
with endogenous thrombin potential 
(C). Anhep, anhepatic phase; Reperf, 
reperfusion phase; PT, prothrombin time; 
APTT, activated partial thromboplastin 
time; ETP, endogenous thrombin 
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postoperative period continuous heparinization led to a clear antico-
agulant effect in most, but not all patients, whereas at day 30 after 
cessation of heparin therapy, there was a hemostatic balance with 
distinct hypercoagulable features. These hypercoagulable features, 
notably a persisting VWF/ADAMTS13 unbalance with normal plate-
let count, hyperfibrinogenemia, and a hypofibrinolytic state may 
contribute to thrombotic risk.
It has previously been demonstrated that a VWF/ADAMSTS13 
unbalance might contribute to the risk of perioperative thrombotic 
complications.26,33,34 In addition, in living donor liver transplantation 
perioperative ADAMTS13 deficiency has been associated with early 
graft dysfunction, which might be related to intrahepatic microthrom-
bosis.35 As isolated ADAMTS13 deficiency could result in (episodic) 
thrombotic microangiopathy, which is successfully prevented by 
plasma exchange, and possibly by administration of ADAMTS13 con-
centrate (ClinicalTrials.gov Identifier: NCT03393975). It may be that 
patients undergoing liver transplantation that have low or undetectable 
ADAMTS13 plasma levels can benefit from ADAMTS13 concentrate.
Although the PT and APTT suggest profound perioperative coag-
ulation failure, thrombomodulin-modified thrombin generation test-
ing shows normal thrombin generating capacity in those samples not 
containing heparin. These results reconfirm that the PT and APTT 
should not be used alone to assess hemostatic status in patients with 
complex alterations in the coagulation system and indicate that pro-
phylactic administration of prohemostatic therapy, with the aim to 
avoid perioperative bleeding, is not justified.9,21,36
The fibrinolytic status varied during liver transplantation, with 
individual patients above or below the reference range at all time 
points measured. On a group level, a clear hyperfibrinolytic state oc-
curred after reperfusion, which is in line with results in adult trans-
plantation.20,37 The subsequent profound hypofibrinolytic state at 
the end of transplantation is also in line with previous observations 
in adult and pediatric transplantation.25,38,39 Although PAI-1 levels 
were elevated in patients at all time points, PAI-1 levels did not fully 
explain the hypofibrinolytic status, and other factors, notably low 
plasminogen levels likely contribute.20,38,40 The persistent high lev-
els of PAI-1 and postoperative hypofibrinolytic state may be clin-
ically relevant because increased PAI-1 levels and prolonged CLT 
are associated with an increased risk of venous and arterial throm-
bosis.41 In a retrospective study from our center, we demonstrated 
that postoperative thrombosis in pediatric liver transplant recipi-
ents mostly emerged at postoperative days 1 to 4.42
F I G U R E  5   Factor II (A), antithrombin 
(B), fibrinogen (C), and factor VIII (D) 
levels at various time points in 20 
pediatric patients during and after liver 
transplantation and 30 healthy controls. 
The small horizontal lines indicate 
medians. Factor levels are given as 
percentages relative to pooled normal 
plasma. Anhep, anhepatic phase; Reperf, 










































































































































**     **     **     **      *       *
A B
C D
F I G U R E  6   Clot lysis time (A) and 
PAI-1 levels (B) at various time points in 
20 pediatric patients during and after 
liver transplantation and in 30 healthy 
controls. The horizontal lines indicate 
medians. Anhep, anhepatic phase; Reperf, 
reperfusion phase; CLT, clot lysis time; 
PAI-1, Plasminogen activator inhibitor 1. 
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Because postoperative thrombosis is one of the main chal-
lenges in contemporary pediatric liver transplantation, routine 
antithrombotic therapy is increasingly used. Most centers have 
included a form of antithrombotic therapy in their clinical prac-
tice, mostly using heparin and/or acetylsalicylic acid.43 Our clin-
ical antithrombotic protocol includes continuous intravenous 
heparin posttransplantation, targeting an APTT of 50-65 seconds, 
replaced by acetylsalicylic acid (19 mg, once daily) after 1 week. 
In our study, targeted APTT levels were not reached in more than 
half of study patients (Figure 4B). This finding might be related to 
the increased use of thromboelastography to guide heparin levels, 
and by clinical aspects, notably perceived risk of ongoing bleeding.
Internationally there is a wide variation in antithrombotic ther-
apy strategies, and there is no consensus about the best therapeutic 
agent and the optimal dose yet. The role of anticoagulant therapy in 
pediatric liver transplantation needs further investigation and clinical 
guidelines should be developed. The results of this study contribute 
to understanding the hemostatic state in these patients, and perhaps 
thrombin generation tests can play an important role in more ratio-
nal anticoagulant management strategies. Note that point-of-care 
thrombin generation tests are in development. Whether current de-
velopment of point-of-care thrombin generation tests will provide a 
solution needs to be determined with further research.
The hypercoagulable features present on day 30 after liver trans-
plantation are in line with those noted in previous studies in adult 
transplantation, showing hypercoagulable features up to 1 year 
after transplantation.20,44 A previous study in pediatric transplanta-
tion found complete normalization of hemostasis at 30 days,39 but a 
very different experimental approach was taken in this study. This 
hypercoagulable state posttransplantation is probably the result of 
low-grade endothelial activation due to immunosuppressive therapy, 
combined with the hyperreactive hemostatic state in these patients. 
The elevated levels of VWF, fibrinogen, and FVIII support this the-
ory. It might be that prolonged antithrombotic therapy is indicated 
after pediatric liver transplantation. Indeed, in adult liver transplan-
tation prolonged administration of acetylsalicylic acid was shown to 
substantially reduce the incidence of late hepatic artery thrombo-
sis.45 Clinical studies will be required to assess safety and efficacy 
of prolonged antithrombotic treatment in the pediatric population.
Although this is a relatively small study, including 20 patients with 
end-stage liver disease, we were able to present a first detailed anal-
ysis of the hemostatic balance in pediatric patients undergoing liver 
transplantation and make a comparison of their hemostatic values 
to that of healthy controls. These results provide novel information 
but need to be confirmed and extended in further studies. It would 
be interesting to explore differences in hemostasis between etiol-
ogies of liver disease and between deceased vs living donor grafts. 
Furthermore, the hemostatic balance in pediatric patients undergoing 
acute liver transplantation or retransplantation needs further explo-
ration, because these patients were excluded from the current study. 
Notably, study patients had relatively short cold ischemia times, and it 
needs to be further investigated if the hemostatic balance changes in 
patients receiving grafts with longer cold ischemia times.
In conclusion, pediatric patients with end-stage liver disease are 
in a fragile hemostatic balance. During transplantation a temporary 
hypocoagulable state is present under heparin administration, which 
rapidly converts to a rebalanced hemostatic state. Distinct hyperco-
agulable features persist until at least day 30, which contribute to 
the risk of posttransplant thrombosis.
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